The small-cap markets have been invaded with a flurry of psychedelics stocks to watch thanks to new company launches. Investors now have a variety of options for taking a run in the shroom stocks space and for researching psychedelic medicine.
In an effort to expand the capabilities of the medical field, companies are starting to investigate the potential of psychedelic medicines and are looking to raise capital in the public market.
While this industry is still in its early stages, the promising potential of psychedelic medicine drug products has attracted the interest of savvy investors — that’s because these psychedelics stocks offer an emerging investment opportunity.
A shroom boom is in the works, led by encouraging results from psychedelic medicine treatments for various issues associated with mental health, and in connection to potential global law changes.
Here the Investing News Network presents a current list of psychedelics stocks to watch. The following stocks are all listed on Canadian public stock exchanges and are arranged alphabetically.
In addition to its recent move into the psychedelics arena, Aion Therapeutic operates in the cannabis industry with a licensed production line in Canada.
As far as its psychedelics business goes, the company’s lead, Dr. Stephen D. Barnhill, has said Aion is pursuing novel formulations of various natural compounds, including psilocybin and fungi.
Algernon Pharmaceuticals (CSE:AGN,OTCQB:AGNPF)
Algernon Pharmaceuticals is a clinical-stage pharmaceutical development company with phase 2 clinical studies being conducted in the disease areas of idiopathic pulmonary fibrosis (IPF), chronic cough and COVID-19.
In Q1 2021, Algernon launched a clinical research program for the treatment of stroke focused on AP-188 (N,N-Dimethyltryptamine or DMT). DMT is a known psychedelic compound that is part of the tryptamine family, which includes psilocybin and psilocin. The company plans to begin a clinical trial as soon as possible in 2021.
Originally a cannabis focused company, Allied Corp began shifting its focus to psilocybin in early 2021. Allied has delivered a fully integrated across the value chain that brings a variety of psilocybin and cannabis formulations to the health and wellness market. The company’s products target the treatment of depression, anxiety and PTSD.
ATAI Life Sciences (NASDAQ:ATAI)
ATAI Life Sciences is a clinical-stage biopharmaceutical company developing novel drugs, including psychedelics, to treat various mental health diseases such as addiction, depression, anxiety, and PTSD. ATAI recently raised US$225 million in a Nasdaq IPO.
Bitoech company Awakn Life Sciences has clinical operations researching, developing, and delivering psychedelic medicine to treat addiction. It is the only company in the world providing evidence-backed ketamine-assisted psychotherapy for alcohol use addiction (AUD) through its near-term Ketamine for Reduction of Alcoholic Relapse (KARE) protocol.
The company recently announced its undertaking a program of clinical research designed to demonstrate the effectiveness for ketamine-assisted psychotherapy against multiple addictions.
BetterLife Pharma (CSE:BETR,OTCQB:BETRF)
BetterLife Pharma is an emerging biotechnology company working to develop and commercialize psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and European Union. The company is also developing drug delivery platform technologies targeting virus infections, such as the coronavirus disease and human papillomavirus (HPV) as well as specific types of cancer.
Better Plant Sciences (CSE:PLNT,OTCQB:VEGGF)
This wellness firm has a substantial investment in the psychedelics market thanks to a majority ownership stake in NeonMind Biosciences, previously known as Flourish Mushroom Labs. According to its parent company, NeonMind will carry out clinical trials on the therapeutic effects of psilocybin.
NeonMind plans to eventually launch branded products such as mushroom-infused items designed to “support immune, cognitive, memory and other brain functions.”
Braxia Scientific (CSE:BRAX,OTC Pink:SHRMF)
Braxia Scientific is developing ketamine and psilocybin derivatives and other psychedelic products from its IP development platform. Additionally, through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., the company owns and operates multidisciplinary community-based clinics providing rapid-onset treatment for mental health disorders. These clinics are located in Mississauga, Toronto, Ottawa, and Montreal.
Braxia Scientific recently launched the Braxia Institute, a training Centre of Excellence focused on advancing psychiatric clinical practice and health services including ketamine and psychedelic treatment therapy for patients with treatment resistant depression and other mental health disorders.
Bright Minds Biosciences (CSE:DRUG,OTCQB:BMBIF)
Bright Minds is a pre-clinical stage company developing a portfolio of next-generation serotonin agonists designed to treat neuropsychiatry disorders, epilepsy and pain. Bright Minds has a portfolio of designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors. These drugs minimizing the side effects of psychedelic and other serotonergic compounds to create superior drugs to first-generation compounds, such as psilocybin.
The company has applied for a listing on the NASDAQ.
Captiva Verde Wellness (CSE:PWR)
This cannabis and hemp company secured an entry point in the psychedelics space by forming a partnership with a Mexican company capable of distributing pharmaceutical and wellness products, including psychoactive and non-psychoactive drugs.
Clearmind Medicine (CSE:CMND)
This biotech company develops IP-protected, novel psychedelic medicines aimed at addressing underserved mental health problems including binge behavior and alcohol use disorder. Clearmind Medicine has granted two patents in the United States, one European patent as well as allowed applications in China and India. The company also has pending divisional applications in Europe and the US related to binge behavior regulators; and a European patent and pending applications in the US, China and India for alcohol beverage substitutes.
Codebase Ventures is an investment firm offering investors a diverse portfolio of opportunities, including a direct stake in Red Light Holland, a publicly traded entity involved in the psychedelics market through its subsidiary Titan Shrooms & Psychedelics.
COMPASS Pathways (NASDAQ:CMPS)
Focused on psilocybin research, COMPASS Pathways has quickly become the center of attention for psychedelics industry watchers. And thanks to a monumental public offering debut, it has attracted interested observers outside the psychedelics arena as well.
The company has been investigating the use of psychedelic compounds to treat depression. In 2018, COMPASS obtained a critical US Food and Drug Administration (FDA) breakthrough therapy designation.
Core One Labs (CSE:COOL,OTC Pink:CLABD)
Core One Labs is looking into the development of psychedelic medicines for a front-facing market.
Thin-film oral strips are one of the potentially novel delivery methods the firm will seek to employ. The company is looking to develop intellectual property related to the psychedelic drug space.
Creso Pharma (ASX:CPH,OTCQB:COPHF)
Pharmaceutical company Creso Pharma develops and produces a wide variety of cannabis and hemp derived therapeutic, nutraceutical, and lifestyle products uses GMP (Good Manufacturing Practice) development and manufacturing standards. The company has worldwide rights for several proprietary drug delivery technologies which enhance the bioavailability and absorption of cannabinoids.
The company recently waded into the psychedelics sector through the recent acquisition of Halucenex Life Sciences Inc. and has a definitive agreement with Red Light Holland to merge, create The HighBrid Lab. The transition to recreational psilocybin includes combined CBD and mushroom products and ready to drink products with mushrooms, CBD and THC.
CURE Pharmaceutical Holding (OTCQB:CURR)
CURE Pharmaceutical Holding is the developer of CUREform, a patented drug delivery platform that has led to a number of immediate- and controlled-release drug delivery vehicles for a wide range of active ingredients designed to improve drug efficacy and safety. The company has a 25,000 square foot, FDA-registered, NSF® and cGMP-certified manufacturing facility
CURE recently commenced development of a psychedelics-based pharmaceutical clinical pipeline to deliver a number of psychedelic compounds.
This life science company is pursuing the development of psychedelic drugs through detailed clinical trials meant to test the efficacy of its candidates.
After going public in Canada, Cybin has moved forward with acquisition deals to expand its market presence in the psychedelics space at large.
Delic Holdings (CSE:DELC,OTCQB:DELCF)
Delic Holdings provides information on psychedelics wellness industry and investment. The company’s product offerings include a blog, podcast, e-commerce store and periodic events.
EGF Theramed Health (CSE:TMED,OTC Pink:EVAHF)
EGF Theramed Health is a medical technology company working on the development of its psychedelics presence. Recently, the company moved forward with a deal to integrate a “seedbank” company holding LSA, an alternative substance to LSD, and other compounds.
Ehave (OTC Pink:EHVVF)
This firm specializes in data solutions for the health space. Ehave is a digital therapeutics firm with a home delivery platform for patients prescribed with ketamine infusions.
Ehave has moved forward with digital solution opportunities for the development of the psychedelics industry, as detailed in a recent shareholder letter.
Empower Clinics (CSE:CBDT,OTC Pink:EPWCF)
This company operates as a healthcare firm involved in various aspects of medical care for patients through clinical and digital solutions.
Empower Clinics got access to the psychedelics space by way of a subsidiary launched to investigate the use of psilocybin for anxiety, depression, post-traumatic stress disorder and addiction.
Entheon Biomedical (CSE:ENBI,OTCQB:ENTBF)
Entheon is a biotechnology company developing a portfolio of safe and effective psychedelic medicines to treat addiction and substance use disorders. The company’s wholly-owned subsidiary HaluGen Life Sciences Inc. had developed a psychedelics genetic test kit available for sale in Canada and the United States.
The psychedelics genetic test kit analyzes a series of relevant DNA biomarkers along with pre-screening mental health surveys to provide insights into an individual’s risk and potential of adverse reactions with the use of hallucinogenic drugs.
Enveric Biosciences (NASDAQ:ENVB)
Enveric Biosciences primary focus until fairly recently was developing novel cannabinoid medicines to improve quality of life for cancer patients adversely affected by the side effects of cancer treatments.
In May 2021, the company entered into a definitive agreement to acquire biotech MagicMed Industries Inc which has been working to create a library of novel derivative psychedelic molecules such as psilocybin and DMT. The acquisition will enable Enveric to expand its portfolio to include psychedelic-derived molecules.
Field Trip Health (TSX:FTRP,NASDAQ:FTRP)
Field Trip Health is trying to encompass the entire new age psychedelics experience. Its primary business is the development of its clinic network across North America. The company opened its first ketamine clinic in Toronto while expanding into the US market via locations in New York and Los Angeles.
In addition to the clinics, Field Trip holds separate divisions, including one that is looking into the research aspect of psychedelic compounds. The company also launched an official app to accompany its treatments, offering patients activities like meditation techniques to go alongside the psychedelics.
Filament Health (NEO:FH)
Filament Health is focused on developing natural psychedelic drug discovery and extraction technology to address the world’s mental health problems. The company has an intellectual property portfolio, in-house GMP facility, and Health Canada Dealer’s License for all natural psychedelics.
Filament plans to produce psychedelic extracts in-house at its GMP-certified facility in Metro Vancouver, and commence the first ever FDA-approved natural-psilocybin clinical trials in Q3 2021.
GH Research (NASDAQ:GHRS)
GH Research is a clinical-stage biopharmaceutical company developing a novel and proprietary 5-MeO-DMT therapies for the treatment of patients with treatment resistant depression. The company’s portfolio includes GH001, a proprietary inhalable 5-MeO-DMT product candidate, and GH002, a proprietary injectable 5-MeO-DMT product candidate.
GH Research has completed a Phase 1 healthy volunteer clinical trial for its GH001 via inhalation product. GH001 is currently being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with treatment resistant depression.
Global Trac Solutions (OTC Pink:PSYC)
This digital media company has dedicated itself to the psychedelics space through its website Psychedelic Spotlight, where it showcases some of the most recent developments for the psychedelics industry.
Goodness Growth Holdings (CSE:GDNS,OTCQX:GDNSF)
Physician-led Goodness Growth Holdings operations primarily consist of its multi-state cannabis company subsidiary, Vireo Health, and its science and intellectual property incubator, Resurgent Biosciences.
In June 2021, the company filed for a U.S. patent to create an expansive suite of virtual reality applications that can be used by practitioners during psychedelic-based therapies to improve patient experience and therapeutic outcomes.
Graph Blockchain (CSE:GBLC)
After embarking on a search for alternative business models to incorporate and support its blockchain technology, Graph Blockchain determined it would acquire Shroom Street in a deal worth C$1 million.
The purchase was done in an attempt to integrate product tracking tools of the much touted blockchain technology into the emerging psychedelics space.
Greenbrook TMS (TSX:GTMS,NASDAQ:GBNH)
Greenbrook TMS operates 129 company-operated treatment centers and is a leading provider of Transcranial Magnetic Stimulation (TMS) therapy, an FDA-cleared, non-invasive therapy for the treatment of major depressive disorder and other mental health disorders.
In July, the company partnered with Cybin to establish Mental Health Centers of Excellence for the purpose of facilitating research and development of innovative psychedelic compound-based therapeutics for patients suffering from depression.
Havn Life Sciences (CSE:HAVN,OTC Pink:HAVLF)
Havn Life Sciences is a newcomer to the psychedelics industry, boasting an impressive lineup of advisors from the Canadian cannabis space. Among these is Vic Neufeld, who used to run Aphria (NASDAQ:APHA,TSX:APHA). Rick Brar, former CEO of Zenabis Global (TSX:ZENA), is another ex-cannabis executive who is on the roster advising the company.
The company holds a Section 56 exemption from Health Canada, meaning it can research and develop psilocybin for scientific use. Havn sells itself to investors as a company investigating psychoactive compounds to develop natural health products.
Hollister Biosciences (CSE:HOLL,OTC Pink:HSTRF)
As a way to pursue exposure to the psychedelic arena, this cannabis player confirmed an acquisition deal worth C$1.2 million for AlphaMind Brands, which, according to the public company, will develop a “portfolio of certified legal mushroom-based natural health products.”
Carl Saling, founder and CEO of Hollister, has called the acquisition a promising opportunity that could complement its cannabis brand business.
KetamineOne Capital (NEO:MEDI,OTC Pink:KONEF)
KetamineOne Capital has a network of 16 mental health clinics across North America. KGK Science Inc., the company’s contract research division, has a 23-year clinical research history and extensive experience in pharmaceuticals, cannabis and the emerging psychedelic medicine industries.
KGK recently applied to Health Canada for a controlled drugs and substances dealer’s licence under Canada’s Narcotic Control Regulations.
This Vancouver-based company has a focus on the development of products and technologies in the emerging psychedelics industry based on high-end medical research.
The company’s current flagship study is a collaboration with the University of Miami. The preclinical study is investigating the treatment of mild traumatic brain injuries/concussions with post-traumatic stress disorder with psilocybin and N-Acetylcysteine.
M2Bio Sciences (OTC Pink:WUHN)
Through its wholly-owned subsidiary MJ MedTech, nutraceutical biotech M2Bio Sciences is focused on plant-based cannabinoids and psilocybin medical research. The company is developing and commercializing a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, Liviana™, and Handcrafted Delights™ brands.
M2Bio Sciences’ research and clinical trials with psilocybin are aimed at developing novel therapies for patients who suffer from alcohol addiction, mental illness and cardiovascular diseases.
Mind Cure Health (CSE:MCUR,OTCQB:MCURF)
Mind Cure Health brings together a variety of medical expertise to pursue the advancement of psychedelics as an active mental health treatment option for patients.
As part of its business, the company wants to develop products with the ability to help enhance mental health and wellness. In addition to its research efforts, it offers a variety of consumer products based on organic mushroom nootropics.
Mind Medicine (MindMed) (NASDAQ:MNMD,NEO:MMED)
MindMed became the first psychedelics firm to make its public debut on Toronto’s NEO Exchange in 2020, earning the attention of investors as part of the new crop of psychedelics stocks to watch.
The company is investigating the use of its 18-MC psychedelic drug candidate as an aid for battling opioid dependency. MindMed has earned the attention of investors thanks to two of its most significant backers: former Canopy Growth (NYSE:CGC,TSX:WEED) CEO Bruce Linton and notorious Dragon’s Den and Shark Tank investor Kevin O’Leary.
Mindset Pharma (CSE:MSET,OTCQB:MSSTF)
This drug development company is pursuing the creation of next-generation “psilocybin-inspired” medicine for unmet medical needs from neurological and psychiatric disorders. Mindset Pharma wants to develop a library of psychedelics-related intellectual property to tackle neuropsychiatric disorders.
Mydecine Innovations Group (OTC Pink:MYCOF,NEO:MYCO)
Formerly known as NewLeaf Brands, Mydecine Innovations Group is advancing new medicine methods, including natural health products. The previous entity acquired Colorado-based Mydecine Group for C$1.2 million. The fungi acquisition was led by Robert Roscow, who served as the director of research with Ebbu, a cannabinoid research company bought by Canadian giant Canopy Growth.
The company holds a portfolio dedicated to the development of its psychedelics business, with three ventures so far: Mydecine Health Sciences, Mindleap Health and NeuroPharm.
New Wave Holdings (CSE:SPOR,OTC Pink:TRMNF)
Investment firm New Wave Holdings offers shareholders an advanced strategy into three segments of the psychedelics space: a recreational product line, a passive cosmetic lineup and the possibility for further high-end medical research-grade items.
New Wave touts a production presence in Jamaica as the core of its psychedelics-based business.
NeonMind Biosciences is a company working with psychedelic compounds for the development of legal products. The company has set a target of treating obesity and related illnesses through its psychedelic products in a preclinical trial.
Nova Mentis Life Science (CSE:NOVA,OTCQB:NMLSF)
Formerly known as cannabis operator Liberty Leaf Holdings, this medical company is exploring the medical benefits of psilocybin. The company has taken steps to solidify its drug development program and holds two subsidiaries: NovaMentis Biotech and Pilz BioScience.
Novamind (CSE:NM,OTC Pink:NVMDF)
Novamind is focusing on ketamine-assisted psychotherapy through clinics available to patients. The company also plans to approach in-depth research on psychedelic compounds to find more applications that are practical for patient use.
The company has longtime cannabis executive Chuck Rifici, who co-founded Canopy Growth, as a member of its board of directors.
Numinus pitches itself to investors as a healthcare firm exploring the compelling new segments of available health treatments to patients. Thanks to specific licensing, the company is capable of operating in the cannabis and psychedelics industries.
Through its Numinus Wellness division, the public company can research the development of psychedelic therapies for treatments related to physical, mental and emotional health.
Nutritional High International (CSE:EAT,OTC Pink:SPLIF)
This primarily cannabis operation acquired an entry into the psychedelics business when it purchased an entity named Psychedelic Science.
The psychedelics division is researching psychedelic cacti strains in the treatment of weight loss, insomnia, anxiety and pain.
Pharmadrug is an international medical company focused on its presence in the European market, thanks to an ownership stake in Pharmadrug GmbH, a German medical cannabis distributor.
The company has gained psychedelics exposure thanks to the key acquisition of Super Smart, a Netherlands-based retailer looking into the legal availability of magic mushrooms in the country.
PharmaTher Holdings (CSE:PHRM,OTCQB:PHRRF)
This company plans to focus on ketamine as its psychedelic drug of choice for research potential. PharmaTher wants to develop new treatments for Parkinson’s disease, depression and general pain.
PsyBio Therapeutics (TSXV:PSYB,OTCQB:PSYBF)
Through the global exclusive rights to a proprietary platform technology, PysBio Therapeutics is developing novel formulations of psychoactive medications produced by naturally in fungi and plants for the treatment of mental health challenges and other disorders.
In July 2021, PsyBio added to its intellectual property portfolio with the filing of a new patent application with the US Patent and Trademark Office for psilocybin and norbaeocystin compositions. PsyBio’s intellectual property portfolio now includes five pending provisional patent applications and one pending non-provisional patent application.
Psyched Wellness (CSE:PSYC,OTCQB:PSYCF)
Psyched Wellness is a health supplements company looking to offer extracted natural oil products.
Besides its product offerings, the company is engaged in various research efforts to look at the medical uses of its products.
Psyence Group (CSE:PSYG)
Psyence Group jumped into the psychedelics listing rush and touts itself as a science-led company with a drug development program in place, including a psilocybin cultivation facility based in Lesotho.
Optimi Health (CSE:OPTI,OTCQB:OPTHF)
Focused on the health and wellness markets, Optimi Health intends to cultivate, extract, process and distribute functional mushroom products at its two facilities nearing completion in British Columbia. The company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of psilocybin and psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a Health Canada dealer’s license.
This firm is focused on a business model of producing and distributing legally sanctioned recreational psilocybin truffles in the Netherlands. The public listing represents a business evolution for the firm as it pursues higher-stakes capital from the market, Chairman and CEO Todd Shapiro said in a statement.
This firm has financial backing from publicly traded investment firm Codebase Ventures.
Revive Therapeutics (CSE:RVV,OTCQB:RVVTF)
Revive Therapeutics bought its way into the promising psychedelic space thanks to a C$2.75 million acquisition agreement with Psilocin Pharma, which has successfully developed unique product formulations for the psilocybin agent.
In the wake of the acquisition deal being announced, Michael Frank, CEO of the public firm, said the deal would add to his company’s “clinical initiatives in liver disease and inflammation.”
Roadman Investments (TSXV:LITT)
In early 2020, this venture capital investment firm confirmed an entry into the new space with a joint venture alongside Psychedelic Insights.
The public firm committed to a US$500,000 injection to kickstart an operation agenda for the joint venture. The goal of this partnership is to create a line of clinics capable of offering guided therapies utilizing the much-promoted psilocybin.
Seelos Therapeutics (NASDAQ:SEEL)
This conventional biopharmaceutical company earned a spot on this list thanks to its validating research involving ketamine therapies.
In 2019, the company was awarded fast-track designation from the FDA for SLS-002, a therapy for acute suicidal ideation and behavior in patients with major depressive disorder.
This company is focused on the biopharmaceutical development process for psilocybin and other psychedelic compounds.
Silo Wellness has indicated it plans to follow an established drug development model, including the possibility of utilizing FDA designations meant to help the process for psychedelic drugs.
Tryp Therapeutics (CSE:TRYP,OTQQB:TRYPF)
This medical company is engaged in the medical investigation of psychedelic compounds for the treatment of rare diseases or conditions with unmet medical treatment.
Tryp Therapeutics is currently researching the use of psilocybin in the treatment of fibromyalgia through its TRP-8802 drug candidate, among other studies with psilocybin.
Wesana Health Holdings (CSE:WESA,OTCQB:WSNAF)
Wesana Health is developing evidence-based formulations and protocols including psilocybin-based therapies for neurological, psychological and mental health ailments.
In addition to its extensive clinical research and academic partnerships, the company recently signed a definitive agreement to acquire Psychedelitech Inc (PsyTech) as a wholly owned subsidiary of Wesana. Through the acquisition, Wesana will benefit from PsyTech’s clinical software-as-a-service (SaaS) platform Tovana Solutions, its integrated mental health practice network Tovana Clinics and PsyTech Connect, the industry’s largest professional psychedelics practitioner community, conferences and educational courses.
Future psychedelics stocks to watch
Investors on the lookout for the most intriguing opportunities in the public space are definitely getting a taste of another early-stage growth segment with the attention the psychedelic market is getting. When it comes to which psychedelics stocks to watch, it’s clear a growing list of names will become available as interest in the space continues to increase.
Don’t forget to follow @INN_LifeScience for real-time updates!
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: Aion Therapeutic, Awakn Life Sciences, Codebase Ventures, Levitee Labs, Lobe Sciences, NeonMind Biosciences, Numinus and Red Light Holland are clients of the Investing News Network. This article is not paid-for content.
Udemy IPO: EdTech Unicorn Filing Information for Investors
Paperwork for the Udemy IPO is now public. The online learning platform is going public on the Nasdaq under the ticker UDMY. Here’s the latest news…
The post Udemy IPO: EdTech Unicorn Filing Information for Investors appeared first on Investment U.
Paperwork for the Udemy IPO is now public for investors. The online learning platform is going public on the Nasdaq under the ticket UDMY. Let’s look at the details…
Udemy IPO: About the Business
Eren Bali, Oktay Caglar and Gagan Biyani founded Udemy in 2010. The three partnered together to achieve a common goal: make quality education accessible to all. The solution was to develop an online learning platform targeted at students and professionals.
Udemy is a massive open online course provider today. The platform has a two-sided marketplace where instructors develop content to meet learner demand. The learning experience combines videos, notes and assessment tests into a series of modules.
The San Francisco-based company has a client base of over 44 million learners in more than 180 countries. Udemy offers over 183,000 courses in 75 languages. Over 73 million users have registered on Udemy since its launch.
Courses are available directly to consumers. The company also offers UDemy Business as its B2B (business to business) learning solution. Organizations can use it to train and develop their employees. 42% of Fortune 100 companies use Udemy Business, according to the filing.
In response to the pandemic, industries have needed to acquire new skills. And ongoing changes in the workplace could make the Udemy IPO an interesting prospect.
Pandemic Accelerates Industries’ Need for New Skills
Changing technologies and new working methods have impacted jobs across the board and made it difficult for workers to keep up. Adapting to rapidly changing conditions is an ongoing challenge for workers across all industries. The roles and activities of workers will have to adapt to new conditions.
The revolution goes far beyond remote working, AI and the use of automated systems. Many people have found a new normal in the workplace. And leaders will need to reskill their workers to deliver new business models in a post-pandemic era.
In a 2021 Workplace Learning Trends Report, Udemy revealed that industries have increased demand for data analysis and data science training.
Data shows companies increased their data modeling training by 466% between 2019 and 2020. In addition, there was an increase of 1,488% in data warehouse training.
This represents a major focus on skills development and continued learning in business. However, the pandemic has affected Udemy in far more ways than just its business platform.
COVID-19 is Reshaping Education Long-Term
A 2020 Udemy report revealed that online education demand increased across all segments as a result of COVID-19. Here are some of the key findings…
- 425% increase in enrollments for consumers
- 55% increase in course creation by instructors
- 80% increase in usage from businesses
Udemy’s prospectus states…
Before the COVID-19 pandemic, the majority of corporate training occurred offline, and we believe that online education is well placed to address the scalability and affordability limitations of offline education. With the increase of internet connectivity, technological advances and interactive tools at a low cost, we expect a massive shift from offline to online.
A 2020 report showed that course enrollments across the Udemy platform grew more than 425% after the first shelter-in-place order took effect. Online learning trends emerged due to the pandemic.
Some of these changes may give a preview of more permanent changes in the way we learn and work in the post-pandemic era. And these trends reflect in Udemy’s revenue and cash flow. Let’s review the company’s finances…
Udemy IPO Financial Data
Revenue: The filing revealed an upswing in revenue. Udemy recorded $276.3 million in revenue for the 2019 fiscal year. In 2020, Udemy’s revenue rose 56% to $429.9 million for the year. Revenue is on track to keep increasing this year. For the six months ended June 2021, the company reported $250.6 million in revenue.
Net Income (Loss): Udemy has reported consistent net losses. For the 2019 fiscal year, the company recorded $69.7 million in net losses. Udemy’s net losses rose to $77.6 million in 2020. For the six months ended July 2021, the company reported $29.4 million net losses. Udemy’s net losses for the half-year ended June 2020 were already $42.5 million, so 2021 should hopefully see declining losses.
Cash: Udemy recorded a massive increase in cash flow in 2020. The company recorded $49.1 million in cash as of December 2019. By the end of 2020, cash skyrocketed to over $175 million. However, the company’s cash decreased to $163.2 million as of June 2021.
Total Assets and Total Liabilities: Udemy’s total assets and total liabilities have grown. The company recorded $117.3 million in total assets and $187.2 million in total liabilities as of December 2019. As of June 30, Udemy’s total assets rose to $286.7 million and total liabilities rose to $279.2 million.
Filing Details for UDMY Stock
Udemy filed confidentially on May 26. The paperwork became public for investors on October 5. However, the company hasn’t set terms for the offering yet. Check out this step-by-step guide to going public to learn more about the initial public offering process.
The company hasn’t announced the number of shares it plans to offer or an expected pricing range for the IPO. Udemy will trade on the Nasdaq exchange under the ticker symbol UDMY.
While the exact terms of the offering are unknown, the company has set a placeholder deal size of $100 million. As a matter of fact, the company is rumored to be targeting an initial valuation of between $6 billion and $8 billion.
As always, make sure to research before you invest. IPOs can be volatile for the first few months and share prices are constantly changing. Moreover, if IPO investing interests you, check out our top recent IPOs and our IPO calendar. We update the calendar daily to give you the latest news on upcoming and filed IPOs.
If you’re looking for the latest investment opportunities, consider signing up for Liberty Through Wealth. This free e-letter is full of market insights from leading experts. You’ll hear from bestselling author and investment expert Alexander Green. It’s one of the easiest ways to stay on top of market news out there. All you need to do is enter your email address in the box below to get started.
The post Udemy IPO: EdTech Unicorn Filing Information for Investors appeared first on Investment U.nasdaq pandemic covid-19
Mark Mahaney reveals his top picks ahead of earnings
The U.S. stock market is likely to be eventful in the upcoming weeks as companies continue to report their quarterly results. Ahead of earnings, Mark Mahaney said Netflix Inc (NASDAQ: NFLX) and Uber Technologies Inc (NYSE: UBER) are set to “outperform”…
The U.S. stock market is likely to be eventful in the upcoming weeks as companies continue to report their quarterly results. Ahead of earnings, Mark Mahaney said Netflix Inc (NASDAQ: NFLX) and Uber Technologies Inc (NYSE: UBER) are set to “outperform” in the fourth quarter.
Mahaney confirms his outperform rating on NFLX
On Friday, Mahaney rated Netflix at “outperform” with a price target of $695 that represents a 10% upside from here.
The Evercore ISI analyst expects a strong content slate to drive much of the growth for the media giant in the fourth quarter. He is convinced that content strength will sustain in 2022 as well.
In August, Netflix resorted to another price hike in Europe that Mahaney says would help boost the average revenue per user. The California-based company recently partnered with Walmart Inc to launch Netflix Hub – a new retail destination focused on Netflix merchandise.
Netflix is set to report its quarterly results on October 19th.
Mahaney sees a 45% upside in Uber Technologies
Also on Friday, Mahaney reiterated Uber at “outperform” with a price target of $70 a share that translates to a roughly 45% upside from here.
His bullish call is partially based on Uber Eats – the fastest-growing U.S. food delivery business. Demand for ride-sharing is also likely to gain traction in the upcoming months as COVID-19 restrictions continue to ease.
At current levels, Uber is a “very attractive” buy, Mahaney added in his research note. The California-based company will report its quarterly results on November 4th. Last month, CEO Dara Khosrowshahi said Uber will hit its profitability milestone ahead of schedule.
The post Mark Mahaney reveals his top picks ahead of earnings appeared first on Invezz.nasdaq covid-19 europe
Best Entertainment Stocks To Invest In Today? 3 Making Headlines
Could entertainment stocks be a good play amidst rising retail sales figures now?
The post Best Entertainment Stocks To Invest In Today? 3 Making Headlines appeared first on Stock Market News, Quotes, Charts and Financial Information | StockMarket.co…
3 Top Entertainment Stocks To Consider Buying [Or Selling] Right Now
The broader stock market today continues to gain as consumer spending power holds strong. Given September’s latest retail sales figures, investors may want to consider looking at the top entertainment stocks now. In brief, retail sales for September surged by 0.7%, according to the Census Bureau earlier today. For reference, Dow Jones economists were expecting a decline of 0.2%. Now, entertainment stocks cater to consumers in good times and bad. Given the current strength in consumer markets and the fast-approaching year-end holidays, we could be looking at exciting times for the industry.
All in all, some would argue that the current momentum in retail spending is rather surprising. This would be the case given fears of the reopening trade losing steam amidst rising consumer prices and the government pulling back its pandemic-era benefits. Moreover, investment banking giant Goldman Sachs (NYSE: GS) crushed analysts’ estimates in its third-quarter earnings call earlier today. The bank posted an earnings per share of $14.93 on revenue of $13.61 billion. Evidently, this is well above projections of $10.18 and $11.68 billion respectively.
Not to mention, notable names in the current entertainment trade continue to break new ground. For example, we could look at the likes of Fubo (NYSE: FUBO) and Roku (NASDAQ: ROKU) this week. Firstly, Fubo is now an authorized gaming operator for NASCAR. Thanks to this partnership, Fubo can now provide racing fans with premium wagering experiences on all their favorite NASCAR races. At the same time, Needham analyst Laura Martin recently hit ROKU stock with a Buy rating. Safe to say, there is no shortage of excitement amongst entertainment stocks in the stock market now. Could one of these names be worth watching now?
Top Entertainment Stocks To Watch This Month
- Canopy Growth Corporation (NASDAQ: CGC)
- Walt Disney Company (NYSE: DIS)
- Roblox Corporation (NYSE: RBLX)
Canopy Growth Corporation
To begin, we have Canopy Growth Corporation, a world-leading diversified cannabis, and cannabinoid-based consumer company. With its ground-breaking innovation and strategic investments, the company offers a wide product variety in high-quality dried flowers, oil, infused beverages, and edibles. The company also has a global medical brand called Spectrum Therapeutics which is a leader in both Canadian and German markets.
On Thursday, the company announced that it will be acquiring Wana Brands, the No. 1 edible cannabis brand in North America. Wana manufactures and sells gummies in the U.S. state of Colorado and licenses its intellectual property to its partners, who manufacture and distribute Wana-branded gummies across the U.S. and Canada. Canopy cited that the strategic benefits of this acquisition would be to strengthen its U.S. ecosystem and also give it market leadership in the edibles product category throughout North America.
Furthermore, Wana also has a profitable and highly scalable business model, with a good track record of generating strong revenue growth and category-leading gross and EBITDA margins. Wana’s proven licensing model also provides the opportunity to scale the brand ahead of U.S. permissibility. Given this strategic play by the company, should you be paying close attention to CGC stock right now?
- 4 Artificial Intelligence Stocks To Watch Right Now
- Best Lithium Battery Stocks To Buy Now? 4 To Know
Walt Disney Company
Disney is a multinational entertainment company with headquarters in Burbank, California. The company is a leader in the animation industry before diversifying into live-action film production, television, and theme parks. DIS stock currently has enjoyed gains of over 35% in the past year alone. Recently, the company unveiled a new plethora of content for its Disney+ streaming service.
This would include 20 new APAC content titles including 18 originals in collaboration with award-winning and aspiring content creators from the region. Furthermore, this would include star-studded scripted live-action tent-pole series in drama, comedy, fantasy to variety shows, documentaries, and anime. Ultimately, this would be part of the company’s aspirations to greenlight over 50 APAC originals by 2023.
The company says that it is making another commitment by combining its global resources with the best content creators from the Asia Pacific to develop and produce original stories for Disney+. With over-the-top services going mainstream, the emergence of world-class content from the Asia Pacific, and rising consumer sophistication, Disney believes that this is the right time for it to deepen its collaboration with the region’s content creators to deliver unparalleled storytelling to global audiences. With this being said, will you consider adding DIS stock to your portfolio?
Another top name to know among entertainment stocks now would be the Roblox Corporation. In essence, the California-based company is a video game developer. Through its proprietary sandbox open-world game of the same name, it continues to make waves across the globe. Through its “human co-experience platform”, millions of players worldwide interact with each other in a vast variety of ways. This ranges from user-built interactive games to pop culture-related content and even live streamable music events in-game.
To date, the company currently boasts an average daily active user count of over 43 million. In its latest fiscal quarter report back in August, the company saw its total revenue skyrocket by 127% year-over-year. Additionally, Roblox also ended the quarter with $1.78 billion in cash on hand, a 186% year-over-year surge. As such, I could see investors eyeing RBLX stock ahead of the company’s upcoming quarterly earnings call on November 8.
Furthermore, Roblox does not seem to be slowing down anytime soon. Just yesterday, the company announced plans to further refine the player experience while monetizing its content. Namely, this will come in the form of more realistic player avatars and new in-game monetization streams. Among the notable additions would be the introduction of limited edition items. The likes of which players can exchange for Robux, a premium in-game currency, which can then be exchanged for actual cash, suggesting an NFT-like system. All things considered, would RBLX stock be a buy for you now?reopening pandemic dow jones nasdaq stocks consumer spending oil canada
The Science Of Propaganda Is Still Being Developed And Advanced
The Bitcoin Rorschach Test
Hot Penny Stocks to Watch As We Turn the Corner on October
Bitcoin Education For Indonesia
The Phillips Curve: What Does It Tell Us About Inflation?
Brace For Price Shock: Americans’ Heating Bills To Soar Up To 50% This Winter
Weekly investment update – Stagflation chatter
The plastic recycling system is broken – here’s how we can fix it
China Coal Prices Soar To Record As Winter Freeze Spreads Cross The Country
Pandemic Wiped Out Entire Savings Of 20% Of US Households
Crypto9 hours ago
The Science Of Propaganda Is Still Being Developed And Advanced
Commodities12 hours ago
The Bitcoin Rorschach Test
Spread & Containment3 hours ago
Huge Dock Worker Protests In Italy, Fears Of Disruption, As Covid ‘Green Pass’ Takes Effect
Bonds15 hours ago
Bitcoin Education For Indonesia
Government19 hours ago
“Expert” Calls For Denying Life-Saving Hospital Treatment To The Unvaccinated
Spread & Containment23 hours ago
‘Animal Crossing: New Horizons’ will get major updates and ‘Happy Home Paradise’ DLC on November 5
Government16 hours ago
4 In 10 TSA Employees Remain Unvaccinated As Deadline Looms
Government20 hours ago
FDA adcomm votes unanimously in support of a J&J Covid-19 booster two months after one-dose shot